Literature DB >> 17311607

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.

T Poynard1, P Halfon, L Castera, F Charlotte, B Le Bail, M Munteanu, D Messous, V Ratziu, Y Benhamou, M Bourlière, V De Ledinghen.   

Abstract

BACKGROUND: The area under the receiver operating characteristic (ROC) curve is widely used as an estimate of the diagnostic value for fibrosis markers. Biopsy length and fragmentation are known as risk factors of false positive or false negative of biopsy but their quantitative impact on area under the receiver operating characteristic curve variability has not been assessed. AIM: To assess these relationships to better compare the fibrosis markers.
METHODS: The area under the ROC curves of FibroTest for the diagnosis of fibrosis was estimated in patients with chronic hepatitis C using an integrated database including 1312 patients with FibroTest and biopsy. To take into account the biopsy length, we used two adjustment factors: one in which an observed area under the ROC curve could be adjusted according to the relative area under the receiver operating characteristic curve of a biopsy of a given length vs. the entire liver and one taking into account the prevalence of each fibrosis stage defining advanced and non-advanced fibrosis.
RESULTS: The mean biopsy length was smaller for cirrhosis (F4, 16 mm) vs. F3, (18 mm, P=0.01) and F0 (19 mm, P=0.01). The mean number of fragments was higher for cirrhosis (F4=4.1 fragments) vs. all the other stages (F0=1.9, F1=1.9, F2=1.9, F3=2.3; P<0.001 vs. F4). The FibroTest area under the ROC curves for the diagnosis of advanced fibrosis, adjusted for stages' prevalence, ranged from 0.80 to 0.98 depending on biopsy length and fragmentation, respectively.
CONCLUSION: The comparison of the area under the ROC curves of fibrosis markers should take into account the biopsy length and fragmentation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311607     DOI: 10.1111/j.1365-2036.2007.03252.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  25 in total

1.  FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

Authors:  Keyur Patel; Mireen Friedrich-Rust; Yoav Lurie; Mircea Grigorescu; Carol Stanciu; Chuan-Mo Lee; Eugene R Schiff; Dieter Häussinger; Michael P Manns; Guido Gerken; Isabelle Colle; Michael Torbenson; Erik Pulkstenis; G Mani Subramanian; John G McHutchison; Stefan Zeuzem
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Authors:  Robert J Fontana; Jules L Dienstag; Herbert L Bonkovsky; Richard K Sterling; Deepa Naishadham; Zachary D Goodman; Anna S F Lok; Elizabeth C Wright; Grace L Su
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

4.  Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

Authors:  Thierry Poynard; Yen Ngo; Mona Munteanu; Dominique Thabut; Vlad Ratziu
Journal:  Curr Hepat Rep       Date:  2011-03-01

5.  Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.

Authors:  Tinsay A Woreta; Catherine G Sutcliffe; Shruti H Mehta; Todd T Brown; Yvonne Higgins; David L Thomas; Michael S Torbenson; Richard D Moore; Mark S Sulkowski
Journal:  Gastroenterology       Date:  2010-12-04       Impact factor: 22.682

6.  External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients.

Authors:  Beom Kyung Kim; Kwang Hyub Han; Jun Yong Park; Sang Hoon Ahn; Chae Yoon Chon; Ja Kyung Kim; Yong Han Paik; Kwan Sik Lee; Young Nyun Park; Do Young Kim
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

7.  Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B.

Authors:  Chang-Feng Dong; Jia Xiao; Ling-Bo Shan; Han-Ying Li; Yong-Jia Xiong; Gui-Lin Yang; Jing Liu; Si-Min Yao; Sha-Xi Li; Xiao-Hua Le; Jing Yuan; Bo-Ping Zhou; George L Tipoe; Ying-Xia Liu
Journal:  World J Hepatol       Date:  2016-05-18

8.  Assessment of liver fibrosis: noninvasive means.

Authors:  Thierry Poynard; Rachel Morra; Patrick Ingiliz; Françoise Imbert-Bismut; Dominique Thabut; Djamila Messous; Mona Munteanu; Julien Massard; Yves Benhamou; Vlad Ratziu
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

9.  Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.

Authors:  Carmen Fierbinteanu-Braticevici; Dan Andronescu; Radu Usvat; Dragos Cretoiu; Cristian Baicus; Gabriela Marinoschi
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 10.  Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C.

Authors:  Rudolf-E Stauber; Carolin Lackner
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.